PP
QNCX icon

PDT Partners’s Quince Therapeutics QNCX Stock Holding History

PDT Partners’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-230
Closed -$61K – 843
2022
Q3 		$61K Sell
230
-827
-78% -$315K 0.01% 805
2022
Q2 		$469K Sell
1,057
-762
-42% -$539K 0.04% 621
2022
Q1 		$2.25M Buy
1,819
+1,407
+342% +$1.91M 0.19% 146
2021
Q4 		$1.04M Buy
+412
New +$2.51M 0.08% 355

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PDT Partners's QNCX Position: Q4 2022 in Review

PDT Partners sold out of Quince Therapeutics (QNCX) in Q4 2022, closing a stake of 230 shares — an estimated $61K sold.

PDT Partners first reported a position in QNCX in Q4 2021 and held it in 4 quarters. The position peaked at $2.25M in Q1 2022. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

  • PDT Partners reported no remaining Quince Therapeutics position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 230 Quince Therapeutics shares in Q4 2022, an estimated $61K.
  • PDT Partners first reported a position in Quince Therapeutics in Q4 2021 and held it in 4 quarters.
  • PDT Partners's Quince Therapeutics position peaked at $2.25M in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.